Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC

[1]  M. Mohty,et al.  Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. , 2019, Clinical lymphoma, myeloma & leukemia.

[2]  M. Labopin,et al.  Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome , 2019, Bone Marrow Transplantation.

[3]  H. Einsele,et al.  Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT , 2018, Haematologica.

[4]  A. Ganser,et al.  Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis , 2018, Bone Marrow Transplantation.

[5]  He Huang,et al.  Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia , 2018, Annals of Hematology.

[6]  A. Vekhoff,et al.  Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  J. Bourhis,et al.  Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire , 2018, American journal of hematology.

[8]  G. Lenz,et al.  High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia , 2018, British journal of haematology.

[9]  J. Esteve,et al.  Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT , 2017, Journal of Hematology & Oncology.

[10]  H. Lazarus,et al.  Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy , 2017, Bone Marrow Transplantation.

[11]  R. Cairoli,et al.  Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience , 2017, International Journal of Hematology.

[12]  A. Ganser,et al.  Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT , 2017, British journal of haematology.

[13]  M. Labopin,et al.  Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia , 2017, Haematologica.

[14]  J. Bourhis,et al.  Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS , 2016, Cancer medicine.

[15]  M. Labopin,et al.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.

[16]  D. Porter,et al.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  K. Takenaka,et al.  Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related C , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Pini,et al.  The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors , 2015, American journal of hematology.

[19]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[20]  M. MacMillan,et al.  Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. , 2015, Blood.

[21]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  R. Porcher,et al.  Relationship between cytomegalovirus (CMV) reactivation, CMV‐driven immunity, overall immune recovery and graft‐versus‐leukaemia effect in children , 2014, British journal of haematology.

[23]  M. Labopin,et al.  Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) , 2014, Bone Marrow Transplantation.

[24]  R. Vij,et al.  Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  A. Elmaagacli.  CMV and relapse: what has conditioning to do with it? , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[26]  B. Sandmaier,et al.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.

[27]  Š. Pospíšilová,et al.  Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia , 2013, Annals of Hematology.

[28]  E. Estey,et al.  Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia , 2013, Haematologica.

[29]  A. Ganser,et al.  Clofarabine‐containing conditioning regimen for allo‐SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT , 2011, European journal of haematology.

[30]  S. Schnittger,et al.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.

[31]  W. Hiddemann,et al.  Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. , 2006, Blood.

[32]  R. Arceci,et al.  Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Kantarjian,et al.  Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. , 2004, Blood.

[35]  D. Follmann,et al.  Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.